Headquartered in Chennai, India, Teyro Labs is a fast-growing generic pharmaceutical company with a major focus on development and manufacture of IP led niche finished dosage formulations and Active pharmaceutical ingredients (APIs). Teyro Labs is involved in Research & Development, Manufacturing and Supply of pharmaceuticals across different geographical entities around the globe. We are always building on our company's core strengths of vertical integration in the fields of discovery, research, process chemistry, active pharmaceutical ingredient production, formulation development and regulatory filings. Teyro Labs, is committed to achieving its vision and mission of invariably becoming the most innovation led transnational pharmaceutical company.
Teyro at Glance
About Us
Inseminating quintessential aspects into our system to satisfy a wide array of criteria, the Teyro Labs always strives to be more and thereby aspire to be the best.Our partnership philosophy with our customers has helped deliver incremental value to both our company and partners. Fulfilling the demands of the world markets - Teyro Labs aim at building on our strong global footprint, we are committed to fulfilling the demands of the world markets by anticipating the future needs and pioneering strategic new in-roads into the commercial pharmaceutical sector. Also, we focus on building an enterprise that generates value for all its stakeholders.We are focused on fulfilling the demands of the world markets through different business segments.
Our Mission & Vision
To be recognized as a leading specialty pharmaceutical company at the forefront of innovation for patients in current challenging and competitive pharmaceutical environment, our business is driven by a strong commitment to quality & compliance and to operating with the highest standards of ethics and integrity. .
We are committed to restoring health and transforming the lives of patients through development of life saving pharmaceutical products.
FACILITY APPROVALS & ACCREDITATIONS
- DUNS verified report by Ministry of Corporate Affairs, GOI
- Certificate of Registration by Department of Scientific & Industrial Research (DSIR)
- cGMP certification by Drugs Control Administration, Government of Tamil Nadu
- cGMP certification by CDSCO & WHO
- Approved by USFDA for Oncology Injectable and Oral solids manufacturing.
- European cGMP inspection (BfArM Germany) process initiated, likely scheduled in Nov-2023
- Teyro Labs is a First generation Pharma company, established in 2015
- State of the art New manufacturing facility commissioned and qualified in 2020-2021 exclusively for manufacture of Oncological products
- This formulations manufacturing facility operates in accordance to international regulatory requirements like USFDA, MHRA, TGA, WHO.
- This facility is built in about 11 Acres with two independent Manufacturing blocks viz. Oncology Finished Dosage Block for Liquid & Lyophilized Injectable, Tablets & Capsules.
- This facility utilizes Isolator technology and RABS (Restricted Access Barrier System) for manufacturing of oncology products which helps to maintain containment control and sterile assurance.
- Teyro Labs has In-house R&D Facilities for Formulation Dosage Forms and Active Pharmaceutical Ingredients (APIs) / Drug Intermediates.
- Formulation R&D facility is located at Oragadam, Chennai (India) and API/ Biotech facility is located at Pondicherry in India
- R&D facility is equipped for complex product development of multiple dosage forms comprising Tablets, Capsules, Liquid & Lyophilized injectable products, PFS, Complex Injectable & etc..
- R&D adopts ‘Quality by Design’ principles and has successfully handled Para-IV and complex new products development for Clients.
- Teyro Lab’s API and Biotech manufacturing facility is in 22 acres, and located at SIPCOT Industrial Complex, Kadikadu, Cuddalore, India
- This API & Biotech drug manufacturing facility is having 4 dedicated manufacturing blocks for Oncology APIs, Large volume General APIs, Small volume General APIs and Fermentation based Immunosuppressant APIs & Enzymes.
- This facility is under commissioning, and shall operate as per international regulatory requirements to cater in-house API requirements and supply to global markets. This facility is expected to be operational by end of 2024.
Biochemistry Tests
quasi architebeat vitae dicta sunt explicabo nemo enim ipsam volup tatem quia voluptassit aspernatur aut odit fugit sed quia consequuntur magni dolores eos qui ratione voluptam sequi nescuntneque porro quisquam.
- The Mycobacteriology Section
- The Aerobic Bacteriology Section
Histopatology Tests
quasi architebeat vitae dicta sunt explicabo nemo enim ipsam volup tatem quia voluptassit aspernatur aut odit fugit sed quia consequuntur magni dolores eos qui ratione voluptam sequi nescuntneque porro quisquam.
- The Mycobacteriology Section
- The Aerobic Bacteriology Section
Designed, Operated & Compliant to meet the regulatory standards as per
